Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. and keeping the price target at $90.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sam Slutsky has given his Buy rating due to a combination of factors surrounding CG Oncology’s recent developments and promising clinical data. The company has initiated a rolling BLA submission for its targeted oncolytic virus, cretostimogene, aimed at treating BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC). This treatment has shown a significant complete response rate and a favorable safety profile, making it a competitive option compared to existing treatments like JNJ’s Inlexzo.
Moreover, cretostimogene’s ability to be active both before and after chemotherapy enhances its potential applicability across different therapy lines. Additionally, the financial outlook is promising, with the cost of Inlexzo being higher than expected, which could position cretostimogene as a cost-effective alternative. The completion of enrollment in the Phase 3 PIVOT-006 study further underscores the company’s progress and potential for future growth, contributing to Slutsky’s positive outlook on CG Oncology’s stock.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $75.00 price target.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is neutral on the stock.